An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

NCT01278849 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Histologically-proven and Radiologically-confirmed Solid Tumors

Interventions

DRUG: ASA404

Sponsor

Novartis Pharmaceuticals